The global Biotechnology market size was valued at USD 761.5 Billion in 2024 and is expected to reach USD 1,315.9 Billion by 2033, growing at a CAGR of 6.27% during the forecast period from 2025 to 2033. Growth is primarily driven by rapid advancements in genetic engineering, increasing R&D in personalized medicine, and rising demand for sustainable agricultural solutions. The biotechnology market encompasses innovations across healthcare, agriculture, and environmental sectors.

Study Assumption Years

• Base Year: 2024
• Historical Years: 2019-2024
• Forecast Period: 2025-2033

Biotechnology Market Key Takeaways

• Current Market Size (2024): USD 761.5 Billion
• CAGR (2025-2033): 6.27%
• Forecast Period: 2025-2033
• Innovation in gene editing technologies, such as CRISPR-Cas9, enhances precise gene modifications impacting healthcare, agriculture, and industrial processes.
• Personalized medicine adoption advances due to genomic sequencing technologies leading to targeted therapies and improved diagnostics.
• Sustainable agriculture needs bolster biotechnological interventions like genetically modified crops and biopesticides.
• North America dominates due to robust research ecosystems, regulatory frameworks, and venture capital investment.
• Integration of AI and machine learning accelerates drug discovery and development processes.

Sample Request Link: 

https://www.imarcgroup.com/biotechnology-market/requestsample

Market Growth Factors

The biotechnology market growth is primarily driven by rapid innovations in gene editing technology. The revolutionary CRISPR-Cas9 technology permits precise gene modifications, enabling new possibilities in medicine, agriculture, and industry. It facilitates gene therapies for genetic disorders and cancers, enhancing personalized treatment avenues. Additionally, genetically engineered microbes contribute to pharmaceutical and industrial production, transforming drug manufacturing processes.

Increasing demands for personalized medicine are propelling market growth. Advanced genomic sequencing techniques allow for detailed genetic analyses, identifying disease-linked variations which enable the development of targeted biopharmaceuticals, such as monoclonal antibodies and gene therapies. Early diagnostics through genetic markers improve prognoses and tailor treatment, shifting the healthcare paradigm towards precision and individualized care.

The rising need for sustainable agriculture solutions also fuels the biotechnology market. Population growth and environmental concerns necessitate sustainable practices such as genetically modified crops engineered for higher yield, pest resistance, and better nutrition. Biopesticides offer environmentally friendly pest control, reducing chemical pesticide use. Biotechnology tools optimize crop traits, improve climate resilience, and boost nutrient use efficiency, directly supporting food security while minimizing ecological footprints.

Market Segmentation

Breakup by Product Type:

• Instruments: Form the foundation of research and diagnostics, enabling precise analysis and experimentation.
• Reagents: Essential components that fuel experimental processes, facilitating accurate results and breakthroughs.
• Software and Services: Software provides data analysis, visualization, and integration solutions enhancing efficiency; services include consulting, training, and technical support fostering effective tool use and collaboration.

Breakup by Technology:

• Nanobiotechnology: Integrates nanoscale materials with biological systems, revolutionizing drug delivery, diagnostics, and therapies.
• Tissue Engineering and Regeneration: Develops functional tissues addressing organ shortages and medical needs.
• DNA Sequencing: Enables comprehensive genomic analysis guiding personalized medicine and disease understanding.
• Cell-Based Assays: Provide insights into cellular behavior, supporting drug development and toxicity testing.
• Fermentation: Core of bioprocessing producing biofuels, pharmaceuticals, and enzymes.
• PCR Technology: Amplifies DNA fundamental for diagnostics and genetic research.
• Chromatography: Separates biomolecules with precision crucial for drug purification and analytics.
• Others: Additional related biotechnologies.

Breakup by Application:

• Healthcare: The largest segment; biotechnology advances diagnostics, treatment development, and personalized medicine leading to improved patient outcomes.
• Food and Agriculture: Includes GMO crops and biopesticides enhancing yield and sustainability.
• Natural Resources and Environment: Biotechnological solutions for environmental management.
• Industrial Processing: Use of biotechnology in manufacturing processes.
• Bioinformatics: Information technology applied to optimize biological research and development.
• Others: Miscellaneous applications.

Breakup by Region:

• North America: United States, Canada
• Asia-Pacific: China, Japan, India, South Korea, Australia, Indonesia, Others
• Europe: Germany, France, United Kingdom, Italy, Spain, Russia, Others
• Latin America: Brazil, Mexico, Others
• Middle East and Africa

Regional Insights

North America currently dominates the biotechnology market owing to its robust ecosystem of research, innovation, and strong industry collaboration. Its substantial investment in R&D and well-established regulatory environment support biotechnological advancements. Leading universities and biotech companies, combined with venture capital emphasis, accelerate commercialization and innovation development, shaping the global biotech landscape and fostering economic and societal impacts.

Recent Developments & News

In May 2025, Biogen and City Therapeutics partnered to develop RNA interference (RNAi) therapies targeting central nervous system diseases. City Therapeutics provides RNAi platform; Biogen leads clinical development and commercialization.

In May 2025, Biocon Biologics launched Ustekinumab BS Subcutaneous Injection [YD] biosimilar in Japan via partner Yoshindo Inc., targeting psoriasis and psoriatic arthritis.

In April 2025, Novartis announced a USD 23 Billion investment over five years in US biotech and pharmaceutical facilities, including new sites and job creation.

Amgen expanded its Ohio biologics manufacturing site with an additional USD 900 Million investment in April 2025, increasing jobs to 750.

In March 2025, Roche opened the Roche Genentech Innovation Center Boston focused on CVRM diseases and AI-driven drug discovery, potentially employing up to 500 staff.

Key Players

• Amgen Inc.
• Biocon Limited
• Biogen Inc.
• F. Hoffmann-La Roche AG
• Genmab A/S
• Lonza Group AG
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Seagen Inc.
• Syngenta AG
• Vertex Pharmaceuticals Incorporated

Get Custom Market Research Report for Your Business:

https://www.imarcgroup.com/request?type=report&id=5785&flag=E

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302